文献速递浆细胞疾病

美法仑氟芬胺或多柔比星联合地塞米松治疗来那度胺难治性多发性骨髓瘤患者(OCEAN):一项随机、头对头、开放标签、3期研究

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
PubMed 文献 · Lancet Haematol · 2022-01-12

OCEAN研究纳入来那度胺难治的复发性/难治性多发性骨髓瘤成人患者,随机接受美法仑氟芬胺+地塞米松或泊马度胺+地塞米松。美法仑氟芬胺组中位无进展生存期6.8个月 vs 泊马度胺组4.9个月(HR 0.79,p=0.032),总生存期无显著差异。

要点

  • 美法仑氟芬胺联合地塞米松较泊马度胺联合地塞米松显著改善无进展生存期
  • 美法仑氟芬胺组3/4级血小板减少和贫血发生率高于泊马度胺组
  • 两组总生存期无显著差异

核心结论

  • 在来那度胺难治的复发性或难治性多发性骨髓瘤患者中,美法仑氟芬胺联合地塞米松的无进展生存期优于泊马度胺联合地塞米松。

研究设计与样本

  • 随机、开放标签、头对头、3期研究(OCEAN),自欧洲、北美和亚洲21个国家的108家大学医院、专科医院和社区中心招募成人患者(年龄≥18岁)。
  • 纳入标准:ECOG体能状态0-2;复发性或难治性多发性骨髓瘤,对来那度胺(随机化前18个月内)和末线治疗难治;既往接受过2-4线治疗(包括来那度胺和蛋白酶体抑制剂)。
  • 患者按1:1随机分配,按年龄、既往治疗线数和国际分期系统评分分层,接受28天周期的美法仑氟芬胺+地塞米松(美法仑氟芬胺组)或泊马度胺+地塞米松(泊马度胺组)。
  • 所有患者在每个周期的第1、8、15、22天口服地塞米松40 mg;美法仑氟芬胺组在每个周期第1天静脉输注美法仑氟芬胺40 mg(30分钟);泊马度胺组在每个周期第1-21天每日口服泊马度胺4 mg。
  • 主要终点为意向治疗(ITT)人群由独立审查委员会评估的无进展生存期;安全性在至少接受一剂研究药物的患者中评估。

主要发现

  • 2017年6月12日至2020年9月3日,246例患者随机分配至美法仑氟芬胺组(中位年龄68岁[IQR 60-72];107例[43%]女性),249例至泊马度胺组(中位年龄68岁[IQR 61-72];109例[44%]女性)。
  • 474例患者至少接受一剂研究药物(美法仑氟芬胺组n=228;泊马度胺组n=246;安全性人群);数据截止日期为2021年2月3日。
  • 美法仑氟芬胺组中位无进展生存期6.8个月(95%CI 5.0-8.5;246例中165例[67%]发生事件)vs 泊马度胺组4.9个月(95%CI 4.2-5.7;249例中190例[76%]发生事件)(HR 0.79,95%CI 0.64-0.98;p=0.032),中位随访时间美法仑氟芬胺组15.5个月(IQR 9.4-22.8),泊马度胺组16.3个月(IQR 10.1-23.2)。
  • 美法仑氟芬胺组中位总生存期19.8个月(95%CI 15.1-25.6),中位随访19.8个月(IQR 12.0-25.0);泊马度胺组25.0个月(95%CI 18.1-31.9),中位随访18.6个月(IQR 11.8-23.7)(HR 1.10,95%CI 0.85-1.44;p=0.47)。
  • 最常见的3级或4级治疗中出现的不良事件:血小板减少(美法仑氟芬胺组228例中143例[63%] vs 泊马度胺组246例中26例[11%])、中性粒细胞减少(123例[54%] vs 102例[41%])、贫血(97例[43%] vs 44例[18%]);严重治疗中出现的不良事件:美法仑氟芬胺组95例(42%)vs 泊马度胺组113例(46%),最常见为肺炎(13例[6%] vs 21例[9%])、COVID-19肺炎(11例[5%] vs 9例[4%])、血小板减少(9例[4%] vs 3例[1%]);致死性治疗中出现的不良事件:美法仑氟芬胺组27例(12%)vs 泊马度胺组32例(13%),其中被认为可能与治疗相关者美法仑氟芬胺组2例(1例急性髓系白血病,1例全血细胞减少和急性心力衰竭),泊马度胺组4例(2例肺炎,1例骨髓增生异常综合征,1例COVID-19肺炎)。

临床怎么用

  • 作者结论认为,在复发性或难治性多发性骨髓瘤患者中,美法仑氟芬胺联合地塞米松的无进展生存期优于泊马度胺联合地塞米松。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provide a progression-free survival benefit compared with pomalidomide plus dexamethasone in patients with previously treated multiple myeloma. METHODS: In this randomised, open-label, head-to-head, phase 3 study (OCEAN), adult patients (aged ≥18 years) were recruited from 108 university hospitals, specialist hospitals, and community-based centres in 21 countries across Europe, North America, and Asia. Eligible patients had an ECOG performance status of 0-2; must have had relapsed or refractory multiple myeloma, refractory to lenalidomide (within 18 months of randomisation) and to the last line of therapy; and have received two to four previous lines of therapy (including lenalidomide and a proteasome inhibitor). Patients were randomly assigned (1:1), stratified by age, number of previous lines of therapy, and International Staging System score, to either 28-day cycles of melflufen and dexamethasone (melflufen group) or pomalidomide and dexamethasone (pomalidomide group). All patients received dexamethasone 40 mg orally on days 1, 8, 15, and 22 of each cycle. In the melflufen group, patients received melflufen 40 mg intravenously over 30 min on day 1 of each cycle and in the pomalidomide group, patients received pomalidomide 4 mg orally daily on days 1 to 21 of each cycle. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat (ITT) population. Safety was assessed in patients who received at least one dose of study medication. This study is registered with ClinicalTrials.gov, NCT03151811, and is ongoing. FINDINGS: Between June 12, 2017, and Sept 3, 2020, 246 patients were randomly assigned to the melflufen group (median age 68 years [IQR 60-72]; 107 [43%] were female) and 249 to the pomalidomide group (median age 68 years [IQR 61-72]; 109 [44%] were female). 474 patients received at least one dose of study drug (melflufen group n=228; pomalidomide group n=246; safety population). Data cutoff was Feb 3, 2021. Median progression-free survival was 6·8 months (95% CI 5·0-8·5; 165 [67%] of 246 patients had an event) in the melflufen group and 4·9 months (4·2-5·7; 190 [76%] of 249 patients had an event) in the pomalidomide group (hazard ratio [HR] 0·79, [95% CI 0·64-0·98]; p=0·032), at a median follow-up of 15·5 months (IQR 9·4-22·8) in the melflufen group and 16·3 months (10·1-23·2) in the pomalidomide group. Median overall survival was 19·8 months (95% CI 15·1-25·6) at a median follow-up of 19·8 months (IQR 12·0-25·0) in the melflufen group and 25·0 months (95% CI 18·1-31·9) in the pomalidomide group at a median follow-up of 18·6 months (IQR 11·8-23·7; HR 1·10 [95% CI 0·85-1·44]; p=0·47). The most common grade 3 or 4 treatment-emergent adverse events were thrombocytopenia (143 [63%] of 228 in the melflufen group vs 26 [11%] of 246 in the pomalidomide group), neutropenia (123 [54%] vs 102 [41%]), and anaemia (97 [43%] vs 44 [18%]). Serious treatment-emergent adverse events occurred in 95 (42%) patients in the melflufen group and 113 (46%) in the pomalidomide group, the most common of which were pneumonia (13 [6%] vs 21 [9%]), COVID-19 pneumonia (11 [5%] vs nine [4%]), and thrombocytopenia (nine [4%] vs three [1%]). 27 [12%] patients in the melflufen group and 32 [13%] in the pomalidomide group had fatal treatment-emergent adverse events. Fatal treatment-emergent adverse events were considered possibly treatment related in two patients in the melflufen group (one with acute myeloid leukaemia, one with pancytopenia and acute cardiac failure) and four patients in the pomalidomide group (two patients with pneumonia, one with myelodysplastic syndromes, one with COVID-19 pneumonia). INTERPRETATION: Melflufen plus dexamethasone showed superior progression-free survival than pomalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. FUNDING: Oncopeptides AB.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022. PMID: 35032434. doi:10.1016/S2352-3026(21)00381-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。